

References

Chapter 8

- 1 Lu Y, Hernandez P, Abegunde D, Edejer T. *The World Medicines Situation 2011. Medicine Expenditures*. Geneva, World Health Organization, 2011.
- 2 Organisation for Economic Co-operation and Development Health Data. Available from: http://stats.oecd.org/index.aspx?DataSetCode=HEALTH_STAT (last accessed 18 November 2015).
- 3 Eurostat Health Database. Available from: <http://ec.europa.eu/eurostat/web/health/health-care/data/database> (last accessed 18 November 2015).
- 4 Organisation for Economic Co-operation and Development. Joint OECD-EUROSTAT-WHO Health Accounts Data-Collection Initiative Launched. *OECD Health Update*. 2006;**2**.
- 5 van Mosseveld C. EUROSTAT's activities in the area of health system comparisons. *European Journal of Public Health*. 2007;**66**–.
- 6 OECD, Eurostat and WHO. *A System of Health Accounts*. Paris, OECD, 2011.
- 7 OECD. *Health at a Glance 2013: OECD Indicators*. Paris, OECD, 2013.
- 8 OECD. *OECD Glossary of Statistical Terms*. Paris, OECD, 2008.
- 9 Vogler S, Habl C, Leopold C, Mazag J, Morak S, Zimmermann N. PHIS Hospital Pharma Report. Vienna, Pharmaceutical Health Information System (PHIS); commissioned by the European Commission and the Austrian Federal Ministry of Health, 2010.
- 10 WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. *Glossary of pharmaceutical terms*. Update 2013. Vienna 2013.
- 11 OECD. *Pharmaceutical Pricing Policies in a Global Market*. *OECD Health Policy Studies*. Paris, OECD, 2008.
- 12 Vogler S, Habl C, Bogut M, Voncina L. Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. *Croatian Medical Journal*. 2011;**52**:197.
- 13 Vogler S, Habl C, Leopold C, Rosian-Schikuta I, de Joncheere K, Lyager Thomsen T. PPRI Report. Vienna, Pharmaceutical Pricing and Reimbursement Information, 2008.
- 14 PPRI Network Members. PPRI/PHIS Posters – country specific reports on different issues related to pharmaceutical systems and policies. *Pharmaceutical Pricing and Reimbursement Information (PPRI)/Pharmaceutical Health Information System (PHIS)*. Vienna, 2007–2013. Available from: <http://whocc.goeg.at/Publications/CountryPosters> (last accessed 18 November 2015).
- 15 PPRI Network Members. PPRI/PHIS Pharma Profiles – country specific reports on pharmaceutical systems and policies. *Pharmaceutical Pricing and Reimbursement Information (PPRI) / Pharmaceutical Health Information System (PHIS)*. Vienna, 2007–2013. Available from: <http://whocc.goeg.at/Publications/CountryReports> (last accessed 18 November 2015).
- 16 Leopold C, Vogler S, Mantel-Teeuwisse AK, de Joncheere K, Leufkens HG, Laing R. Differences in external price referencing in Europe – a descriptive overview. *Health Policy*. 2012;**104**:50–60.
- 17 Leopold C, Mantel-Teeuwisse AK, Seyfang L, Vogler S, de Joncheere K, Laing RO, Leufkens H. Impact of external price referencing on medicine prices – a price comparison among 14 European countries. *Southern Med Review*. 2012;**5**(2):34–41.
- 18 PPRI Secretariat. *Pharmaceutical policy monitoring exercise with national competent authorities represented in the PPRI network* (unpublished). Bi-annually, latest update: September 2014. *Pharmaceutical Pricing and Reimbursement Information (PPRI)*, 2014.
- 19 Vogler S. How large are the differences between originator and generic prices? Analysis of five molecules

- in 16 European countries. *Farmeconomia Health Economics and Therapeutic Pathways*. 2012;**13**:29–41.
- 20** Kanavos P, Vandoros S, Irwin R, Nicod E, Casson M. *Differences in Costs Of and Access To Pharmaceutical Products in the EU*. Brussels, European Parliament, 2011.
- 21** Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries – an overview. *Generics and Biosimilars Initiative (GaBI) Journal*. 2012;**1**:93–100.
- 22** PHIS database: https://phis.goeg.at/index.aspx?_nav0029.
- 23** Kanavos P, Schurer W, Vogler S. *Pharmaceutical Distribution Chain in the European Union: Structure and Impact on Pharmaceutical Prices*. London/Vienna, EMINet/LSE/GÖG, 2011.
- 24** Vogler S, Pertl D, Schmickl B, Windisch F. Apothekenhonorierung in Europa [Pharmacy remuneration in Europe]. Vienna, Gesundheit Österreich Forschungs- und Planungsgesellschaft mbH, 2014.
- 25** Vogler S. Preisbildung und Erstattung von Arzneimitteln in der EU – Gemeinsamkeiten, Unterschiede und Trends. *Pharmazeutische Medizin*. 2012;**14**:56.
- 26** Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. *Lancet*. 2009;**373**:240–9.
- 27** Ball D. Working Paper 3: Regulation of Mark-Ups in the Pharmaceutical Supply Chain – Review Series on Pharmaceutical Pricing Policies and Interventions. Geneva, World Health Organization and Health Action International, 2011.
- 28** Levison L, Laing R. The hidden costs of essential medicines. *Essential Drugs Monitor*. 2003;**33**:20–1.
- 29** WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. Glossary of pharmaceutical terms. Latest update of print version: 2011; regularly updated online. Vienna, World Health Organization, 2011.
- 30** Godman B, Bennie M, Baumgärtel C, et al. Essential to increase the use of generics in Europe to maintain comprehensive health care? *Farmeconomia Health Economics and Therapeutic Pathways*. 2012;**13**:5–20.
- 31** Habl C, Vogler S, Leopold C, Schmickl B, Fröschl B. Referenzpreissysteme in Europa. Analyse und Umsetzungsvoraussetzungen für Österreich. Vienna: ÖBIG Forschungs- und Planungsgesellschaft mbH, 2008.
- 32** Kanavos P, Seeley L, Vandoros S. Tender systems for outpatient pharmaceuticals in the European Union: evidence from the Netherlands, Germany and Belgium. European Medicines Information Network (EMINet), 2009.
- 33** Lopes S, Marty C, Berdai D. PHIS Pharma Profile France. Vienna, Pharmaceutical Health Information System (PHIS), 2011.
- 34** Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A. Discounts and rebates granted to public payers for medicines in European countries. *Southern Med Review*. 2012;**5**:38–46.
- 35** Espín J, Rovira J, García L. Experiences and Impact of European Risk-Sharing Schemes Focusing on Oncology Medicines. EMINet, 2011.
- 36** Adamski J, Godman B, Ofierska-Sujkowska G, Osipińska B, Herholz H, Wendykowska K, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. *BMC Health Services Research*. 2010;**10**:153.
- 37** Vogler S, Zimmermann N, Mazag J. Procuring medicines in hospitals: results of the European PHIS survey. *EJHP Practice*. 2011:20–1.
- 38** Vogler S, Zimmermann N, Leopold C, Habl C, Mazag J. Discounts and rebates granted for medicines for hospital use in five European countries. *Open Pharmacoeconomics & Health Economics Journal* 2013;**5**:1–10.
- 39** Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems.
- 40** Espin J, Rovira J, de Labry AO. Working Paper 1: External Price Referencing – Review Series on Pharmaceutical Pricing Policies and Interventions. Geneva, World Health Organization and Health Action International, 2011.
- 41** Gesundheit Österreich GmbH (Austrian Health Institute). Pharma Price Information (PPI) service. Available from: <http://www.goeg.at/en/PPI> (last accessed 18 November 2015).
- 42** Bouvy J, Vogler S. Background paper 8.3. Pricing and reimbursement policies: impacts on innovation. In: World Health Organization. *Priority Medicines for Europe and the World 'A Public Health Approach to Innovation' Update on 2004 Background Paper*. Geneva, World Health Organization, 2013.

-
- 43 World Health Organization and Health Action International (HAI). *Medicine Prices: A New Approach to Measurement. Working Draft for Field Testing and Revision*. Geneva, World Health Organization, 2003.
 - 44 World Health Organization and Health Action International. *Measuring Medicine Prices, Availability, Affordability and Price Components*, 2nd edn. Geneva, World Health Organization, 2008.
 - 45 European Pharmaceutical Marketing Research Association (EphMRA). *EphMRA Lexicon: A Pocket Guide to Pharmaceutical Marketing and Marketing Research Terms and Definitions*.
 - 46 WHO Collaborating Centre for Drug Statistics Methodology. Use of ATC/DDD. Available from: http://www.whocc.no/use_of_atc_ddd/ (last accessed 18 November 2015).
 - 47 Danzon PM, Kim JD. International price comparisons for pharmaceuticals. *Pharmacoeconomics*. 1998;**14**:115–28.
 - 48 Hill P. International price levels and purchasing power parities. *OECD Economic Studies*. 1986;**6**:133–59.
 - 49 Danzon PM, Furukawa MF. Prices and availability of pharmaceuticals: evidence from nine countries. *Health Affairs*. 2003;W3-521.
 - 50 Danzon PM, Furukawa MF. International prices and availability of pharmaceuticals in 2005. *Health Affairs*. 2008;**27**:221–33.
 - 51 Kanavos PG, Vondoros S. Determinants of branded prescription medicine prices in OECD countries. *Health Economics Policy and Law*. 2011;**6**:337.
 - 52 Kanavos P, Ferrario A, Vondoros S, Anderson GF. Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs. *Health Affairs*. 2013;**32**:753–61.
 - 53 Brekke KR, Holmås TH, Straume OR. Are Pharmaceuticals Still Inexpensive in Norway? A Comparison of Prescription Drug Prices in Ten European Countries. SNF Report No. 08/10. 2010.
 - 54 Paris V, Belloni A. Value in Pharmaceutical Pricing. OECD Health Working Papers, No. 63. Paris, OECD, 2013.
 - 55 von der Schulenburg F, Vondoros S, Kanavos P. The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors. *Health Economics Review*. 2011;**1**:1–8.
 - 56 Simoons S. International comparison of generic medicine prices. *Current Medical Research and Opinion*. 2007;**23**:2647–54.
 - 57 Tafuri G, Creese A, Reggi V. National and international differences in the prices of branded and unbranded medicines. *Journal of Generic Medicines*. 2004;**1**:120–7.